Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history

Abstract Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additiona...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Thomas W. McDade, Alexis R. Demonbreun, Amelia Sancilio, Brian Mustanski, Richard T. D’Aquila, Elizabeth M. McNally
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/8e2609c3fe644fae88cd30f4096e7e76
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8e2609c3fe644fae88cd30f4096e7e76
record_format	dspace
spelling	oai:doaj.org-article:8e2609c3fe644fae88cd30f4096e7e762021-12-02T16:38:25ZDurability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history10.1038/s41598-021-96879-32045-2322https://doaj.org/article/8e2609c3fe644fae88cd30f4096e7e762021-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-96879-3https://doaj.org/toc/2045-2322Abstract Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.Thomas W. McDadeAlexis R. DemonbreunAmelia SancilioBrian MustanskiRichard T. D’AquilaElizabeth M. McNallyNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Thomas W. McDade Alexis R. Demonbreun Amelia Sancilio Brian Mustanski Richard T. D’Aquila Elizabeth M. McNally Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history
description	Abstract Two-dose messenger RNA vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective in preventing symptomatic COVID-19 infection. However, the durability of protection is not known, nor is the effectiveness against emerging viral variants. Additionally, vaccine responses may differ based on prior SARS-CoV-2 exposure history. To investigate protection against SARS-CoV-2 variants we measured binding and neutralizing antibody responses following both vaccine doses. We document significant declines in antibody levels three months post-vaccination, and reduced neutralization of emerging variants, highlighting the need to identify correlates of clinical protection to inform the timing of and indications for booster vaccination.
format	article
author	Thomas W. McDade Alexis R. Demonbreun Amelia Sancilio Brian Mustanski Richard T. D’Aquila Elizabeth M. McNally
author_facet	Thomas W. McDade Alexis R. Demonbreun Amelia Sancilio Brian Mustanski Richard T. D’Aquila Elizabeth M. McNally
author_sort	Thomas W. McDade
title	Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history
title_short	Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history
title_full	Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history
title_fullStr	Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history
title_full_unstemmed	Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history
title_sort	durability of antibody response to vaccination and surrogate neutralization of emerging variants based on sars-cov-2 exposure history
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/8e2609c3fe644fae88cd30f4096e7e76
work_keys_str_mv	AT thomaswmcdade durabilityofantibodyresponsetovaccinationandsurrogateneutralizationofemergingvariantsbasedonsarscov2exposurehistory AT alexisrdemonbreun durabilityofantibodyresponsetovaccinationandsurrogateneutralizationofemergingvariantsbasedonsarscov2exposurehistory AT ameliasancilio durabilityofantibodyresponsetovaccinationandsurrogateneutralizationofemergingvariantsbasedonsarscov2exposurehistory AT brianmustanski durabilityofantibodyresponsetovaccinationandsurrogateneutralizationofemergingvariantsbasedonsarscov2exposurehistory AT richardtdaquila durabilityofantibodyresponsetovaccinationandsurrogateneutralizationofemergingvariantsbasedonsarscov2exposurehistory AT elizabethmmcnally durabilityofantibodyresponsetovaccinationandsurrogateneutralizationofemergingvariantsbasedonsarscov2exposurehistory
_version_	1718383585230061568

Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history

Ejemplares similares